This study is currently not recruiting participants.

Randomized Placebo-Controlled Double Blind Multicenter Study to Assess the Efficacy Safety and Tolerability of Arikace in Cystic Fibrosis Patients with Chronic Infection Due to Pseudomonas Aeruginosa

Investigational Medication for Lung Infections

Not Recruiting
18 years - 100 years
All
Phase N/A
1 Location

Brief description of study.

This study is being done to learn the effects (good and bad) of ArikaceTM on lung infections.

Detailed description of study

This study is being done to learn the effects (good and bad) of ArikaceTM on lung infections.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Cystic Fibrosis
  • Age: 18 years - 100 years
  • Gender: All

This study investigates the effects of an investigational medication on lung infections. Lung infections occur when harmful bacteria or viruses invade the lungs, causing symptoms like coughing, fever, and difficulty breathing.

Participants in the study will receive either the investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medicine but does not contain any medicine. The study will monitor the effects and safety of the medication.

  • Who can participate: Participants must be adults aged 18 years or older with a confirmed diagnosis of a lung infection. Additional eligibility criteria include no history of allergic reactions to similar medications and adequate lung function as determined by the study team.
  • Study details: Participants will be given either the investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medicine but does not contain any medicine.
Updated on 19 Feb 2024. Study ID: 1107006246

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team